Drug development company NeuroRx Inc revealed on Monday that Aviptadil has been identified by the National Institutes of Health (NIH) as one of two drugs selected for inclusion in the upcoming phase III multicentre COVID-19 clinical trial across the US and other countries.
The company added that Aviptadil is being developed under the name ZYESAMI in collaboration with Relief Therapeutics Holding AG (SIX:RLF,OTCQB:RLFTF).
Designated as TESICO (Therapeutics for Severely Ill Inpatients with COVID-19), the trial is funded by the US Government COVID-19 Therapeutics Response and sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).
Upon review and approval as phase III trial by the US Food and Drug Administration, TESICO will randomly allocate 640 participants to Aviptadil, Remdesivir, the combination of both drugs and placebo. Remdesivir is marketed as Veklury by Gilead Sciences (Nasdaq:GILD).
In addition, the primary endpoint of the TESICO COVID trial will be participant recovery from respiratory failure over 90 days. Additional information will be supplied by the NIH when the trial randomizes its first patients, concluded the company.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial